LYEL
Lyell Immunopharma
$12.96
+$0.33 (+2.61%)Jul 27, 2026
Key metrics
The numbers that frame LYEL today
- Market cap
- $302.41M
- P/E (TTM)
- -1.2
- EV / FCF
- -1.9
- Gross margin
- 100%
- EV / Sales
- 8,604.9
- ROIC
- -87.9%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $9.28
- 52wk High
- $45.00
Growth
Revenue and earnings trend for LYEL
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about LYEL
Is Lyell Immunopharma a good buy?
No. Lyell Immunopharma has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks weak. That could put pressure on the long-term business case. We think Lyell Immunopharma is selling at a very high price.
What is the market capitalization of LYEL?
Lyell Immunopharma's market capitalization is $302.41M.
What is the P/E ratio for LYEL stock?
Lyell Immunopharma's current P/E ratio is -1.2.
What is the 52-week high for LYEL stock?
The 52-week high for Lyell Immunopharma is $45.00. The current close of $12.96 is 71.2% below that high.
What is the 52-week low for LYEL stock?
The 52-week low for Lyell Immunopharma is $9.28. The current close of $12.96 is 39.7% above that low.
Does LYEL stock pay dividends?
Lyell Immunopharma does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for LYEL?
Lyell Immunopharma's Debt / Equity ratio is 0.14.